MX2019001670A - Terapia con rapamicina topica. - Google Patents

Terapia con rapamicina topica.

Info

Publication number
MX2019001670A
MX2019001670A MX2019001670A MX2019001670A MX2019001670A MX 2019001670 A MX2019001670 A MX 2019001670A MX 2019001670 A MX2019001670 A MX 2019001670A MX 2019001670 A MX2019001670 A MX 2019001670A MX 2019001670 A MX2019001670 A MX 2019001670A
Authority
MX
Mexico
Prior art keywords
conditions
topical rapamycin
rapamycin therapy
rapamycin
topical
Prior art date
Application number
MX2019001670A
Other languages
English (en)
Spanish (es)
Inventor
Kay Koenig Mary
Northrup Hope
A Hebert Adelaide
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2019001670A publication Critical patent/MX2019001670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019001670A 2016-08-10 2017-08-10 Terapia con rapamicina topica. MX2019001670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662372940P 2016-08-10 2016-08-10
PCT/US2017/046320 WO2018031789A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Publications (1)

Publication Number Publication Date
MX2019001670A true MX2019001670A (es) 2019-07-04

Family

ID=59684091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001670A MX2019001670A (es) 2016-08-10 2017-08-10 Terapia con rapamicina topica.

Country Status (11)

Country Link
US (1) US20190167649A1 (https=)
EP (1) EP3496712A1 (https=)
JP (1) JP2019527711A (https=)
KR (1) KR20190039220A (https=)
CN (1) CN109689053A (https=)
AU (1) AU2017311491A1 (https=)
BR (1) BR112019002689A2 (https=)
CA (1) CA3032473A1 (https=)
MX (1) MX2019001670A (https=)
RU (1) RU2019106483A (https=)
WO (1) WO2018031789A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
WO2019156999A1 (en) * 2018-02-06 2019-08-15 Georgetown University TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CA3110108A1 (en) * 2018-08-30 2020-03-05 Chemistryrx Sirolimus containing compositions
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
US20200261427A1 (en) 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
WO2020175131A1 (ja) * 2019-02-27 2020-09-03 国立大学法人大阪大学 脈管異常治療用外用剤
WO2021149827A1 (ja) * 2020-01-24 2021-07-29 ノーベルファーマ株式会社 ラパマイシン含有外用剤
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
AU2023203871B1 (en) * 2023-06-20 2024-07-25 Aft Pharmaceuticals Ltd A Rapamycin Method of Treatment and Composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
AU2003259803B2 (en) 2002-08-12 2007-08-02 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
RU2007130406A (ru) 2005-03-02 2009-04-10 Вайет (Us) Очистка рапамицина
KR20080090493A (ko) 2006-02-02 2008-10-08 노파르티스 아게 결절성 경화증의 치료
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
AU2014209141B2 (en) * 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CA3037469C (en) * 2015-09-24 2024-04-16 Drexel University Treatment of dermal disorders comprising a mtorc1 inhibitor
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途

Also Published As

Publication number Publication date
KR20190039220A (ko) 2019-04-10
CA3032473A1 (en) 2018-02-15
RU2019106483A3 (https=) 2020-12-04
WO2018031789A1 (en) 2018-02-15
JP2019527711A (ja) 2019-10-03
BR112019002689A2 (pt) 2019-05-14
EP3496712A1 (en) 2019-06-19
RU2019106483A (ru) 2020-09-11
AU2017311491A1 (en) 2019-02-07
CN109689053A (zh) 2019-04-26
US20190167649A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX2019001670A (es) Terapia con rapamicina topica.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MY201925A (en) Macrocyclic compounds and uses thereof
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
MX393974B (es) Terapia de combinacion para tratamiento de cancer.
SG10201907684PA (en) Androgen receptor modulator and uses thereof
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2017015896A (es) Agente anticancerigeno.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ760459A (en) Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
NZ716033A (en) Treatment of papulopustular rosacea with ivermectin
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
EP4335517A3 (en) Administration and dosage of diaminophenothiazines
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
EP4309738A3 (en) Method of treating medulloblastoma with an ezh2 inhibitor
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
AU2017356887A8 (en) sGC stimulators
MX2019003603A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
BR112018014769A2 (pt) ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos?
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
EP4268899A3 (en) Ferritin nanoparticles comprising a chemotherapeutic agent
EA201892813A1 (ru) Иммунотерапия рака